Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TMVR in Patients with Multivalvular Heart Disease with Dr Kimberly Holst
Author(s): Kimberly Holst Added: 3 months ago
Navigate the strategic complexities of transcatheter mitral valve replacement in multivalvular disease with Dr Kimberly HolstThis presentation, part of Women As One's comprehensive Structural Interventions track, provides a systematic framework for approaching multivalvular heart disease. The presentation establishes the foundational principle of strategic intervention sequencing in high-risk… View more

Intervention
ESC 25 Discussion: 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
Author(s): Harriette Van Spall , Michael Andrew Borger Added: 4 months ago
ESC Congress 2025 - Dr Harriette Van Spall (McMaster University, Canada) sits down with Professor Michael Borger (University of Leipzig Heart Center, Germany), Co-Chair of the newly released 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease.The new guidelines bring together the latest evidence and expert consensus on how to diagnose, evaluate, and treat patients with valvular… View more

Guidelines & Statements

Imaging & Diagnostics
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 4 months ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements
ERA 25: Albuminuria, eGFR Dip and Disease Severity & Empagliflozin
Author(s): William Herrington Added: 8 months ago
ERA 2025 - Findings from a meta-analysis of chronic kidney disease outcomes in patients treated with empagliflozin suggest that people with CKD benefit from the drug irrespective of diabetes of albuminuria status.ProfWilliam Herrington (University of Oxford, Oxford, UK) joins us to discuss outcomes from an individual patient-level data meta-analysis, investigating the impact of diabetes,… View more

Cardiovascular Renal Metabolic
ERA 25: eGFR Dips and Disease Severity on Empagliflozin
Author(s): Added: 8 months ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of… View more

Cardiovascular Renal Metabolic
Navigating Mitral and Tricuspid Valve Disease: Diagnosis, Quality of Life, and Patient-Centered Care
Author(s): Suzanne Arnold , Colin Barker, Start date: Aug 06, 2025
Mitral and tricuspid regurgitation remain under-recognised and undertreated despite their significant impact on symptoms, quality of life, and outcomes. In this expert-led webinar, Suzanne V. Arnold, MD (Saint Luke’s Health System, Kansas City, US) offers practical guidance on recognising heart valve disease early, navigating referral pathways, and integrating patient-centred data into everyday… View more

Intervention
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Author(s): Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al Added: 9 months ago

Prevention & Chronic Conditions
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Diversity in Cardiovascular Disease: Are we Failing the General Population?
Author(s): Martha Gulati Added: 1 year ago
In this video series recorded at ACC 2024 in Atlanta, US, Prof Martha Gulati (Cedars-Sinai Smidt Heart Institute, Los Angeles, US) unveils pivotal data from four posters addressing the pressing issue of inequality in cardiology and healthcare. Gain a deeper understanding of personalised treatment approaches, recognise the importance of inclusivity in clinical trials and confront disparities in… View more

CV Disease in Special Populations
EHRA 24: AI-Enabled Single-Lead ECG Can Unmask Conduction Tissue Disease
Author(s): Laurent Fiorina Added: 1 year ago
EHRA 24 - In this short interview, we are joined by Dr Laurent Fiorina (Cardiovascular Institute Paris-Sud (ICPS), FR) joins us to discuss the findings from a clinical investigation into diagnosing conduction tissue disease using an AI-enabled single-lead coronary ECG device.This observational, prospective clinical trial aims to investigate the performance of an artificial intelligence algorithm… View more

Imaging & Diagnostics

Electrophysiology & Arrhythmia